Maintenance Therapy with Intravesical Bacillus Calmette-Guerin in Patients with Intermediate- or High-risk Non-muscle-invasive Bladder Cancer

Bacillus Calmette-Guérin Without Maintenance Therapy for High-Risk Non–Muscle-Invasive Bladder Cancer

European Urology ◽

10.1016/j.eururo.2011.03.051 ◽

2011 ◽

Vol 60 (1) ◽

pp. 32-36 ◽

Cited By ~ 46

Author(s):

Harry W. Herr ◽

Guido Dalbagni ◽

Sherri M. Donat

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Maintenance Therapy ◽

Invasive Bladder Cancer ◽

Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?

European Urology Open Science ◽

10.1016/j.euros.2021.01.009 ◽

2021 ◽

Vol 26 ◽

pp. 35-43

Author(s):

Michael E. Rezaee ◽

A. Aziz Ould Ismail ◽

Chiamaka L. Okorie ◽

John D. Seigne ◽

Kristine E. Lynch ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Intravesical Therapy ◽

Cancer Outcomes ◽

Safety evaluation of sequential Mitomycin and Bacillus Calmette-Guérin treatment versus Bacillus Calmette-Guérin monotherapy in patients with high risk non-muscle invasive bladder cancer: MITOBCG study (EUDRACT Number 2017-004540-37) preliminary results

European Urology ◽

10.1016/s0302-2838(21)00829-0 ◽

2021 ◽

Vol 79 ◽

pp. S618-S619

Author(s):

C. De Nunzio ◽

A. Nacchia ◽

R. Lombardo ◽

O.A. Voglino ◽

V. Baldassarri ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Safety Evaluation ◽

Invasive Bladder Cancer ◽

Preliminary Results ◽

The Optimal Timing of Restaging Resection before Introduction of Bacillus Calmette-Guerin Immunotherapy in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer

Urologia Internationalis ◽

10.1159/000491642 ◽

2018 ◽

Vol 102 (1) ◽

pp. 60-68 ◽

Cited By ~ 2

Author(s):

Wojciech Krajewski ◽

Romuald Zdrojowy ◽

Janusz Dembowski ◽

Sławomir Poletajew ◽

Michał Wróbel ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Optimal Timing ◽

Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC)

World Journal of Urology ◽

10.1007/s00345-019-02896-3 ◽

2019 ◽

Vol 38 (6) ◽

pp. 1517-1524 ◽

Cited By ~ 3

Author(s):

Clara Delcourt ◽

Pierre Gemival ◽

François Xavier Nouhaud ◽

Françoise Gobet ◽

Andre Gillibert ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Predictive Factor ◽

Invasive Bladder Cancer ◽

Immuno Histochemistry ◽

Clinical Interest ◽

Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin

BJU International ◽

10.1111/bju.13102 ◽

2015 ◽

Vol 116 (5) ◽

pp. 721-726 ◽

Cited By ~ 17

Author(s):

Sümer Baltacı ◽

Murat Bozlu ◽

Asıf Yıldırım ◽

Mehmet İlker Gökçe ◽

İlker Tinay ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Transurethral Resection ◽

Invasive Bladder Cancer ◽

Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure

Current Urology ◽

10.1097/cu9.0000000000000010 ◽

2021 ◽

Vol 15 (1) ◽

pp. 33-38

Author(s):

Govind Shantharam ◽

Ali Amin ◽

Jorge Pereira ◽

Ohad Kott ◽

Catrina Mueller-Leonhard ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

European Urology Open Science ◽

10.1016/s2666-1683(20)33372-3 ◽

2020 ◽

Vol 19 ◽

pp. e1173-e1174

Author(s):

J.L. Boormans ◽

R. De Wit ◽

G.S. Kulkarni ◽

E.M. Uchio ◽

M. Roumiguié ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Phase 2 ◽

Phase 2 Study ◽

Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder Cancer

European Urology Supplements ◽

10.1016/j.eursup.2010.08.005 ◽

2010 ◽

Vol 9 (9) ◽

pp. 715-734 ◽

Cited By ~ 20

Author(s):

Donald Lamm ◽

Raj Persad ◽

Marc Colombel ◽

Maurizio Brausi

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Standard Of Care ◽

Invasive Bladder Cancer ◽

PD19-07 ONE-YEAR FOLLOW-UP RESULTS AFTER SEQUENTIAL INTRAVESICAL BACILLUS CALMETTE-GUÉRIN AND DEVICE-ASSISTED CHEMO-HYPERTHERMIA (MITOMYCIN C DELIVERED BY THE COMBAT BRS SYSTEM) FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS...A BACILLUS CALMETTE-GUÉRIN-SPARING STRATEGY

The Journal of Urology ◽

10.1016/j.juro.2017.02.880 ◽

2017 ◽

Vol 197 (4S) ◽

Cited By ~ 1

Author(s):

TR Leyshon Griffiths ◽

William JF Green ◽

Peter T Grice ◽

Jonathan C Goddard ◽

Roger C Kockelbergh

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Cancer Patients ◽

Mitomycin C ◽

Invasive Bladder Cancer ◽

Muscle Invasive ◽

One Year